Identifying biomarkers for predicting outcomes in liver cancer treatments
Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for Hepatocellular Carcinoma (HCC)
University of Texas Southwestern Medical Center · NCT04459468
This study is trying to find new blood markers that can help predict how well liver cancer treatments work for patients undergoing standard procedures.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University of Texas Southwestern Medical Center (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT04459468 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enroll patients with hepatocellular carcinoma who are scheduled for locoregional treatments such as Lipiodol TACE, denovo ablation, or Y90 radioembolization. Blood samples will be collected before and after these standard care procedures to identify novel proteomic biomarkers using a bead-based X-aptamer library. The goal is to validate these biomarkers and create a panel that can predict treatment outcomes for HCC patients. The study is prospective and non-blinded, focusing on patients aged 18 to 70 years.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-70 diagnosed with primary or metastatic liver cancer scheduled for specific locoregional treatments.
Not a fit: Patients who have previously received chemotherapy, radiation, or surgery for HCC may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction of treatment outcomes for patients with hepatocellular carcinoma.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for cancer treatment outcomes, but this specific approach using X-aptamer libraries is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ability to understand and the willingness to sign a written informed consent. 2. Male or female aged 18-70years. 3. Diagnosed with primary or metastatic liver cancer. 4. Scheduled to undergo Lipoidal TACE, denovo ablation, or Yttrium-90 (Y90) radioembolization as part of standard of care. Exclusion Criteria: Subjects who have received chemotherapy, radiation or surgery for HCC.
Where this trial is running
Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas, United States (RECRUITING)
Study contacts
- Study coordinator: Claire Starcke, BS
- Email: Charlton.Starcke@UTSouthwestern.edu
- Phone: 214-648-8152
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatocellular Carcinoma